Manuel Rosa-Calatrava

Manuel Rosa-Calatrava has worked in the field of medical research since 2005 when they began as a Research Director (DR2) and Permanent Researcher (CR1) at the National Institute of Health and Medical Research (INSERM). In 2010, they became the Co-Director of the VirPath Laboratory at CIRI U1111 INSERM - UMR5308 CNRS - ENS Lyon - UCBL1, where they worked on different aspects of respiratory virus biology, from virus emergence and pathogenesis to the analysis of viral interplays with cells and host factors during respiratory virus infection. In 2021, they became the Co Director of the RespiVIR International Associated Laboratory at Universit\u00e9 Claude Bernard Lyon 1 - Universit\u00e9 Laval. That same year, they also became a member of the Programmation and Prospective Committee at Centre Jacques Cartier. In 2019, they became an Associate Co-founder of VAXXEL, a spin-off of the Universit\u00e9 Claude Bernard Lyon1 and the Virpath laboratory. In 2017, they became an Associate Co-founder of SIGNIA THERAPEUTICS, a spin-off of Universit\u00e9 Claude Bernard Lyon1. In 2011, they became the Co-founder and Director of the VirNext Platform, a spin-off of Universit\u00e9 Claude Bernard Lyon 1 (UCBL1). In 2010, they became the Head of the Molecular and Cellular of Influenza Signature, Vaccine and Antivirals team at VirPath. In 2014, they became the Director of the Joint Industrial Laboratory BIOVIRSAFE, a joint research laboratory between VirPath and Produit Sanitaire A\u00e9ronef (PSA) SME. In 2022, they will become an Associate Co-founder of VirexpR.

Throughout their career, Manuel Rosa-Calatrava has worked on a broad range of respiratory virus facets from surveillance to control, virus/bacteria co-infection issues, host epithelium mucosal responses, air treatment and respiratory protection technologies, antiviral drug discovery, and the development of innovative live attenuated bivalent vaccine candidates.

Manuel Rosa-Calatrava received their PhD from the Université de Strasbourg between 1997 and 2001. Manuel then obtained a Certificat en Propriété intellectuelle from the Center for International Intellectual Property Studies - CEIPI in 2001. In 2006, they completed a DU Valorisation de la recherche appliquée et biomédicale from Pierre and Marie Curie University. In 2008, they attended IHEDN. Finally, they received a Master Class in Intellectual Property from INPI between 2015 and 2016.